Novavax (NVAX) is back in focus after Q3 2026 results and new detail on its vaccine partnership with Sanofi, including a triggered US$125 million milestone tied to a Phase 3 combination trial.
Recent trading shows how quickly sentiment around Novavax can swing. The 1-day share price return of 10.22% and 7-day share price gain of 6.94% come after a 30-day share price return that fell 3.92%. However, the 90-day share price return of 35.60% and year-to-date share price gain of 51.19% point to momentum rebuilding as investors react to the Sanofi milestone and the better-than-expected Q3 update, even as the 5-year total shareholder return is still down 93.65%.
Spot fast-moving vaccine and biotech stories similar to Novavax by scanning our handpicked 39 high quality undervalued stocks list, featuring companies with resilient balance sheets and room for sentiment to keep shifting.
For Novavax, the bullish story leans on Sanofi milestones and a narrower loss, while the bear case points to shrinking sales and heavy past value destruction. Which side current pricing leans toward becomes a key question as valuation comes into focus.
Most Popular Narrative: 25% Undervalued
At a last close of $10.78 versus a narrative fair value of $14.44, Novavax is framed as undervalued, with that gap linked directly to confidence in its Matrix M licensing model and leaner cost base.
The shift to a partner-led Matrix-M licensing model, with 4 of the top 10 global pharmaceutical companies now using licenses or MTAs across more than 30 infectious disease and oncology projects, supports the case that Novavax could grow higher margin royalty and milestone revenue over time.
See why 66 investors see Novavax as 25% undervalued .
Result: Fair Value of $14.44 (UNDERVALUED)
Still, the Novavax narrative leans heavily on partner milestones and royalty flows, and past revenue declines with ongoing losses could quickly challenge that "undervalued" label.
Find out about the key risks to this Novavax narrative .
Another View: Novavax On Sales Ratios
The narrative fair value of $14.44 leans on future earnings and cash flows. A simpler cross check looks at today's sales multiple. Novavax trades on a P/S of 4.3x, while the US Biotechs industry sits at 9.6x and peer averages are 15.4x, yet the fair ratio is just 1.5x. For anyone watching NVAX, is that a margin of safety or a pricing trap if sales keep shrinking?
To see how this pricing gap ties back to the numbers and where the P/S ratio might move over time, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Plenty of strong opinions surround Novavax right now. Move quickly, test the numbers yourself, and weigh both sides of the story using 2 key rewards and 2 important warning signs .
Looking for more ideas beyond Novavax?
If Novavax has sharpened your focus, do not stop here. Use the Simply Wall St screener to pressure test fresh opportunities before the crowd notices.
-
Spot potential mispricings early and scan a curated 19 high quality undiscovered gems that highlights businesses with fundamentals the market may be overlooking.
-
Reduce volatility shocks by focusing on a 29 resilient stocks with low risk scores that filters for resilience when markets turn choppy.
-
Strengthen portfolio quality by targeting a list of solid balance sheet and fundamentals (24 results) that surfaces companies built on sturdier financial footing.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVAX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
